159 related articles for article (PubMed ID: 9710226)
1. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease.
Moiola L; Galbiati F; Martino G; Amadio S; Brambilla E; Comi G; Vincent A; Grimaldi LM; Adorini L
Eur J Immunol; 1998 Aug; 28(8):2487-97. PubMed ID: 9710226
[TBL] [Abstract][Full Text] [Related]
2. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
3. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
Balasa B; Deng C; Lee J; Bradley LM; Dalton DK; Christadoss P; Sarvetnick N
J Exp Med; 1997 Aug; 186(3):385-91. PubMed ID: 9236190
[TBL] [Abstract][Full Text] [Related]
4. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
5. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.
Karachunski PI; Ostlie NS; Monfardini C; Conti-Fine BM
J Immunol; 2000 May; 164(10):5236-44. PubMed ID: 10799884
[TBL] [Abstract][Full Text] [Related]
6. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.
Shi FD; Bai XF; Li HL; Huang YM; Van der Meide PH; Link H
Clin Exp Immunol; 1998 Mar; 111(3):506-12. PubMed ID: 9528890
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice.
Sitaraman S; Metzger DW; Belloto RJ; Infante AJ; Wall KA
J Neuroimmunol; 2000 Jul; 107(1):73-82. PubMed ID: 10808053
[TBL] [Abstract][Full Text] [Related]
8. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
[TBL] [Abstract][Full Text] [Related]
9. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis.
Ostlie NS; Karachunski PI; Wang W; Monfardini C; Kronenberg M; Conti-Fine BM
J Immunol; 2001 Apr; 166(8):4853-62. PubMed ID: 11290761
[TBL] [Abstract][Full Text] [Related]
10. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
11. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.
Deng C; Goluszko E; Tüzün E; Yang H; Christadoss P
J Immunol; 2002 Jul; 169(2):1077-83. PubMed ID: 12097416
[TBL] [Abstract][Full Text] [Related]
12. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor.
Ma CG; Zhang GX; Xiao BG; Link J; Olsson T; Link H
J Neuroimmunol; 1995 Apr; 58(1):51-60. PubMed ID: 7537280
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis.
Wang HB; Li H; Shi FD; Chambers BJ; Link H; Ljunggren HG
Int Immunol; 2000 Oct; 12(10):1381-8. PubMed ID: 11007755
[TBL] [Abstract][Full Text] [Related]
15. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice.
Li H; Shi FD; He B; Bakheit M; Wahren B; Berglöf A; Sandstedt K; Link H
Int Immunol; 1998 Sep; 10(9):1359-65. PubMed ID: 9786435
[TBL] [Abstract][Full Text] [Related]
16. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
[TBL] [Abstract][Full Text] [Related]
17. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells.
Ma CG; Zhang GX; Xiao BG; Wang ZY; Link J; Olsson T; Link H
Ann N Y Acad Sci; 1996 Feb; 778():273-87. PubMed ID: 8610980
[TBL] [Abstract][Full Text] [Related]
18. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor.
Shenoy M; Oshima M; Atassi MZ; Christadoss P
Clin Immunol Immunopathol; 1993 Mar; 66(3):230-8. PubMed ID: 7679342
[TBL] [Abstract][Full Text] [Related]
19. IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.
Huda R; Strait RT; Tüzün E; Finkelman FD; Christadoss P
J Neuroimmunol; 2015 Apr; 281():68-72. PubMed ID: 25867470
[TBL] [Abstract][Full Text] [Related]
20. Experimental autoimmune myasthenia gravis in the mouse.
Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
